FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11^th, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com

About Cytek Biosciences

Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek's FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Other than Cytek's Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek's products are for research use only – not for use in diagnostic procedures or for clinical purposes.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

Investor Relations Contact:

Paul D. Goodson

Head of Investor Relations

pgoodson@cytekbio.com

Media Contact:

Stephanie Olsen

Lages & Associates

(949) 453-8080

stephanie@lages.com

Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022